Hematological malignancy
Conditions
Interventions
Sponsors
Kurashiki Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Hematological malignancy for AML, MDS, CML, ALL, ML and MM 2. Performance status(PS, ECOG) of 0-2 3. Patients without major organ dysfunction 4. T.Bil less than 2.0 mg/dL 5. AST and ALT less than 3 upper limit of the normal range 6. SCr less than 2.0mg/dl 7. Heart ejection fraction more than 40% 8. SpO2 more than 93% 9. Patients requird to have an appropriate donor identified before enrollment. (1) HLA-matched related or unrelated donor (2) 1 HLA-mismatched related or unrelated donor (3) Cord blood with nucleated cell counts more than 1.5 107/kg and mismatched HLA less than 2 10. Ability to provide informed consent.
Exclusion criteria
Exclusion criteria: 1. positive for anti-HIV antibody 2. positive for Hbs antigen 3. active another malignancy 4. uncontrollable psychological disorders 5. uncontrollable active infection 6. known hypersensitivity to busulfan 7. pregnant women 8. Patients judged as inappropriate for this study by physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients with event-free survival in 100 days after transplantation | — |
Countries
Japan
Contacts
Public ContactAki Sato
Kurashiki Central Hospital Department of Hematology / Oncology
Outcome results
None listed